How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant KEYNOTE 522?

This is probably the single most difficult subtype of breast cancer to treat as it tends to be horribly chemo insensitive and molecularly most are actually luminal B and not basal. If growing on the carbon/Taxol/pembro portion of KEYNOTE, I would switch immediately to AC/pembro with a low threshold ...